CNS (Central Nervous System) Viral Dynamics and Cellular Immunity During AIDS

NCT ID: NCT00583167

Last Updated: 2014-05-28

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 4 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2006-03-31
• Study Completion Date: 2010-07-31

Brief Summary

Understanding whether or not viral replication occurs in the brain during chronic untreated HIV-1 infection is of undeniable importance, and has implications for treatment and research priorities. Evidence suggests that viral replication in the CNS occurs at the extremes of HIV-1 disease. Brain involvement has been reported during acute infection, and there is convincing evidence of CNS viral replication during HIV-associated dementia (HAD) and advanced AIDS. Some human and primate data suggest that viral RNA and proteins may be absent from brains of some individuals with chronic untreated HIV-1 infection despite abundant proviral DNA. However, the extent of viral replication in the brain is not known for most of the 42 million people worldwide living with untreated HIV-1 infection.

Why is viral replication in the brain such a pivotal issue? Microglial cells and macrophages are primary targets for intrathecal HIV-1 replication, and this can promote neuronal injury through direct effects of gp120 and tat, and indirect induction of toxic mediators. Low-grade injury over years or decades would likely be deleterious, particularly as the population ages. Because treatment guidelines allow systemic HIV-1 replication to continue until CD4+ T cell counts decline considerably, antiretroviral therapy (ART) is not recommended for many persons living with HIV. Demonstrating replication in the brain during chronic HIV-1 infection may affect treatment strategies and encourage investigation.

Identifying factors that modulate intrathecal viral replication is equally important. Anti-HIV-1 cytotoxic T lymphocytes (CTL) partially control systemic viral replication and delay disease progression. Although available data has been provocative, the role of anti-HIV CTL in the CNS has received little attention. To fill this gap we will examine relationships between intrathecal viral replication, CTL responses, and glial activation/proliferation during HIV-1 infection. These studies will be relevant not only to AIDS but to other inflammatory diseases of the CNS as well.

Conditions

HIV Infections

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

A1

HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA \>20,000 copies/mL. CD4+ T cell count \>200 cells/mm3. Group A1 will undergo continuous CSF ( cerebrospinal fluid) sampling via intrathecal catheter.

No interventions assigned to this group

A2

HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA \>20,000 copies/mL. CD4+ T cell count \<200 cells/mm3. Group A2 will undergo continuous CSF sampling via intrathecal catheter.

No interventions assigned to this group

B

HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA \>20,000 copies/mL. Group B will not undergo continuous CSF sampling, but will undergo sparse CSF sampling by lumbar punctures.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• (All subjects in Groups A1, A2 and B):
• At least 18 years of age.
• No more than one month of ART in the past.
• No ART in the previous 3 months.
• Platelet count >100,000 cells/mm3 on most recent determination within 60 days prior to first study lumbar puncture.
• Normal prothrombin time (PT) and partial thromboplastin time (PTT) on most recent determination within 60 days prior to first study lumbar puncture.
• Among individuals with past ART experience, the ability to construct an ART regimen predicted to completely suppress plasma HIV-1 RNA, based on results of viral susceptibility testing that is done as a routine part of clinical practice.
• Plasma HIV-1 RNA >20,000 copies/mL.
• Group A1:
• CD4+ T cell count >200 cells/mm3.
• CSF HIV-1 RNA >2,000 copies/mL on screening lumbar puncture.
• No history of significant allergy to beta lactam antibiotics, including penicillins and cephalosporins.
• No history of allergy to vancomycin.
• Group A2:
• CD4+ T cell count <200 cells/mm3.
• CSF HIV-1 RNA >2,000 copies/mL on screening lumbar puncture.
• No history of significant allergy to beta lactam antibiotics, including penicillins and cephalosporins.
• No history of allergy to vancomycin.

Exclusion Criteria

• Evidence of CNS opportunistic infections or space occupying lesion.
• History of significant CNS disorder unrelated to HIV infection such as trauma, congenital malformations or genetic disorders.
• History of seizures.
• As determined by the investigator, a significant active or previous history of cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, or endocrine disease(s) that would interfere with study participation.
• Evidence or suspicion of vascular or Alzheimer's type dementias.
• Evidence or suspicion of Parkinson's disease.
• History of allergy to lidocaine.
• Implanted metal objects that make MRI contraindicated. This may require consultation with colleagues in the Vanderbilt Dept. of Radiology.
• Women who are pregnant or breastfeeding.
• Women with a positive pregnancy test on enrollment or prior to study drug administration.
• Women of childbearing potential (WOCBP) who are unwilling or unable to use an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized.
• Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institutes of Health (NIH)

NIH

Sponsor Role: collaborator

Vanderbilt University

OTHER

Sponsor Role: lead

Responsible Party

David Haas

Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

David W. Haas, MD

Role: PRINCIPAL_INVESTIGATOR

Vanderbilt University

Locations

Vanderbilt AIDS Clinical Trials Center

Nashville, Tennessee, United States

Countries

United States

Other Identifiers

R01MH071205

Identifier Type: NIH

Identifier Source: secondary_id

View Link

050001

Identifier Type: -

Identifier Source: org_study_id